Drug Database
BL

blood substitute (Volplex / Volplex)

✓ Approved

Sinclair · Cell-based Therapies · Cell-based Therapies

What is blood substitute?

blood substitute is a cell-based therapies developed by Sinclair. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesVolplex, Volplex
CompanySinclair
Drug ClassCell-based Therapies
RouteInjectable (Others), Intravenous (IV)
StatusApproved

Therapeutic Indications

blood substitute is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresAdjuvant therapy✓ Approved

Related Research Articles

PubMedChemPlusChem2026-08-31

Synergistic Role of Co0 and Lewis Basic Sites for Transfer Hydrogenation of Substituted Nitroarenes by In Situ Hydrogen Generation.

Sharma Anitya A, Ramchiary Dhanmani D, Sharma Devendra D, Kumar Sahil S et al.

Designing green and efficient methods for synthesizing anilines remains a key challenge in synthetic organic chemistry. Hydrogenation of nitro compounds is one of the most significant and widely employed method for producing functionalized anilines. Consequently, designing catalytic systems capable of hydrogenating nitroarenes under environmentally benign and mild reaction conditions remains a challenge. In this regard, a highly efficient CoAl catalyst has been designed for the hydrogenation of nitroarenes to corresponding amines. Various structural, compositional, and morphological characterizations were done to understand the catalyst's structural and surface properties. The as-synthesized catalyst exhibits excellent activity for the transfer hydrogenation of 1-chloro-4-nitrobenzene to 4-chloroaniline, achieving 98% yield at 60 °C within 1.5 h in ethanol. The developed protocol demonstrated excellent activity for wide range of substituted nitroarenes. Structure-activity relationships of CoAl show that basic sites play a crucial role in the transfer hydrogenation. Furthermore, mechanistic investigations reveal that transfer hydrogenation occurs predominantly via a hydroxylamine-mediated pathway. Moreover, the catalyst maintains good catalytic activity up to four consecutive cycles. This method eliminates the need for high-pressure H2, offering a safe strategy for aromatic amine synthesis. The work demonstrates the potential of earth-abundant, non-noble-metal-based heterogeneous catalysts for hydrogenation reactions under environmentally benign conditions.

PubMedWater research2026-08-30

Threshold-driven reuse of mineral processing water: selective treatment and AI-ready monitoring for fit-for-purpose control.

Wang Sen S, Ren Yancheng Y, Zheng Ziqi Z, Su Yuhang Y et al.

Flotation process-water reuse is increasingly necessary in mineral processing, yet recycled water is a chemically active process stream rather than a neutral freshwater substitute. This review reframes flotation water reuse as an AI-enabled fit-for-purpose management problem that links water-quality mechanisms, threshold evaluation, selective upgrading, and intelligent control. Evidence from sulfide, phosphate, and spodumene systems shows that accumulated ions, residual reagents, fine particles, dissolved organics, and microbial activity interact to affect flotation performance. Water-quality thresholds should be treated as process-specific decision bands, not universal numerical limits. The proposed AI architecture fuses online sensors, laboratory confirmation, ore information, reagent history, and recycle-time data for water-state recognition, soft-sensing prediction of difficult-to-measure contaminants, flotation-response forecasting, adaptive threshold correction, and treatment-routing decision support. Within this architecture, model selection should be governed by decision-time data availability, chronological validation, uncertainty quantification, and operational fallback. An offline proof-of-concept using a public industrial iron-ore flotation dataset demonstrates process-quality prediction and illustrative context-dependent threshold switching. Because the dataset contains no recycled-water chemistry or water-balance measurements, the exercise does not validate freshwater saving, economic benefit, treatment routing, or industrial closed-loop control. The proposed framework instead specifies the data, fail-safe mechanisms, validation metrics, and techno-economic analysis and life-cycle assessment requirements needed for future plant-scale evaluation.

PubMedNeuro-oncology advances2026-08-30

Development of a novel analytical pipeline to characterize morphological and molecular features of blood vessels within marginal regions of glioblastoma.

Das Anubrata A, Vallatos Antoine A, Birch Joanna J, Ireson Christopher C et al.

Glioblastomas (GBM) are highly invasive tumors with marginal regions comprising unresectable functional brain infiltrated by tumor cells. Effective drug delivery to these regions is crucial, but lack of understanding of the structural and functional characteristics of their vasculature is impeding drug development. We aimed to develop a bespoke analytical pipeline that could be used to characterize molecular and morphological features of the blood-brain barrier within marginal regions of GBM by analyzing image descriptors extracted from multiplex colorimetric imaging of human samples. Multiplex immunohistochemical consecutive staining of key vascular antigens was performed on human samples of GBM and adjacent brain to determine the morphology and composition of blood vessels. A neural network was utilized to segment the vessels, and multiple image descriptors extracted to characterize and classify them with a Linear Discriminant model. Multiplexed immunohistochemistry was optimized for vessel related-antigens CD31, laminin, claudin-5, smooth muscle actin, platelet-derived growth factor beta, and glial fibrillary acidic protein. Multiple parameters analyzed from the segmented blood vessels were modeled into four distinct categories, linked to region-specific molecular and morphological factors. Margin regions exhibited the lowest vessel density and a heterogenous mix of vessels with some unique to the region and others similar to tumor core or normal brain vessels. We established a multiplex immunohistochemical staining protocol and pipeline to identify blood vessels and analyze their composition. The pipeline and the preliminary quantitative data it generated will facilitate more comprehensive characterization of margin-specific blood vessels, with implications for drug development.

PubMedPakistan journal of medical sciences2026-08-30

Pattern of blood utilization and blood wastage at blood bank of a tertiary care hospital in Lahore.

Akhtar Asma A, Saeed Naureen N, Muzaffar Ahsen A, Mughal Zunairah Z

To analyze pattern of blood component utilisation and determine the extent and causes of blood wastage in the blood bank of a tertiary care hospital in Lahore. A retrospective observational study was conducted at the Blood Bank of Shalamar Hospital, Lahore, from January 1, 2022 and December 31, 2023.Board. Data on the number and type of blood components prepared, issued, and discarded were retrieved from blood bank record. Causes of blood wastage, including expiry, transfusion reactions, delayed return after issuance, broken bags or seals, and haemolysed or clotted units, were reviewed. Data were analyzed using SPSS version 24, and results were expressed as frequencies and percentages. A total of 9,406 blood donations were collected. Of these, 8129 units were issued to clinical departments, while 1,277 units were discarded, resulting in wastage rate of 13.5%. Whole blood (41.8%) and red cell concentrates (36.8%) were most frequently utilized. The Intensive Care Unit (21.4%), Gynecology and Obstetrics (19.9%), and Medical units (16.7%) were the leading end users. Expired units accounted for 96% of blood wastage, with fresh frozen plasma forming the largest proportion (45%). Whole blood and red cell concentrates were the most commonly used components. Blood wastage exceeded international benchmarks, with expiry as the predominant cause. Regular audits, rational ordering, and adherence to transfusion guidelines are essential to optimize utilization and minimize losses.

PubMedJournal of ophthalmology2026-08-30

Assessing Guideline Knowledge Alignment of Large Language Models in Ophthalmology: A Preclinical Benchmarking Study on KLEx Evidence-Based Guidelines.

Lu Hongxia H, Huo Yan Y, Xie Ruisi R, Qu Zhengyuan Z et al.

To evaluate the guideline knowledge alignment of two large language models (LLMs), GPT-5.5 Instant and DeepSeek-V4, and to determine their preclinical reliability as reference tools in refractive surgery. Using the 38 evidence-based recommendations of the international keratorefractive lenticule extraction (KLEx) guidelines as the gold standard, both LLMs were evaluated in their default configurations. Two ophthalmologists independently assessed the clinical safety and medical accuracy of the model responses using a 5-point Likert scale (1-5 points). Agreement between each model's recommendation strength and the guideline was quantified by intraclass correlation coefficient (ICC), structural reliability by the DISCERN scale, and readability by the Flesch Reading Ease (FRE) and Flesch-Kincaid Grade Level (FKGL) indices. Likert ratings did not differ between GPT-5.5 Instant (4.96 ± 0.206) and DeepSeek-V4 (4.89 ± 0.385; p = 0.134). Across 114 independent generations, the ICC for agreement with the guideline was 0.884 (95% CI, 0.836-0.918) for GPT-5.5 Instant and 0.739 (0.640-0.813) for DeepSeek-V4 (both p < 0.001). DISCERN scores were 70.18 ± 5.16 and 68.05 ± 5.41 (p = 0.085); FRE, 9.93 ± 8.33 and 3.74 ± 5.24 (p < 0.001); and FKGL, 16.07 ± 2.21 and 18.95 ± 1.96 (p < 0.001). Both models aligned closely with the guidelines, with significant concordance in GRADE-based recommendation strength. They may serve as preclinical reference tools in refractive surgery but not as a substitute for specialist judgment.

PubMedJournal of molecular histology2026-08-30

Anti-LCN2 antibody treatment is associated with attenuated hearing loss and blood-labyrinth barrier disruption in a mouse model of chronic kidney disease.

Ding Ye Y, Jiang Xin X, Ye Xiangming X

Chronic kidney disease (CKD) is associated with sensorineural hearing loss, but the mechanisms linking renal injury to cochlear dysfunction remain incompletely defined. Because lipocalin-2 (LCN2/NGAL) is markedly increased in CKD and has been implicated in endothelial dysfunction and barrier injury, we investigated whether LCN2 contributes to cochlear damage in a mouse model of CKD. Male C57BL/6J mice underwent 5/6 nephrectomy, and CKD mice received either an anti-LCN2 monoclonal antibody or an isotype control three times weekly for seven weeks beginning one week after completion of surgery. Auditory function, cochlear morphology, blood-labyrinth barrier integrity, cochlear perfusion, and LCN2-associated signaling were assessed using auditory brainstem responses, distortion product otoacoustic emissions, whole-mount immunofluorescence, FITC-dextran extravasation, Western blotting, quantitative PCR, and laser Doppler flowmetry. CKD mice developed elevated auditory brainstem response thresholds, reduced distortion product otoacoustic emission amplitude at a single primary tone pair with f2 = 8.0 kHz, outer hair cell loss, and a reduction in the number of CtBP2-positive presynaptic ribbon puncta per inner hair cell. These changes were accompanied by increased serum and cochlear LCN2, upregulation of 24p3R/SLC22A17 and NLRP3, increased blood-labyrinth barrier permeability, reduced claudin-5 and ZO-1 expression, impaired cochlear blood flow, stria vascularis atrophy, and decreased expression of strial ion-transport genes. Anti-LCN2 antibody treatment improved auditory thresholds and otoacoustic emission responses, attenuated outer hair cell and synaptic injury, reduced vascular leakage, partially restored tight junction and ion-transport gene expression, and improved cochlear perfusion, without measurably lowering serum blood urea nitrogen or creatinine. These findings support a possible contribution of LCN2 to CKD-associated cochlear vascular dysfunction and hearing loss. Targeting LCN2 may represent a therapeutic strategy for preserving hearing in CKD, although validation in additional CKD models, both sexes, and human tissues is required.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about blood substitute